These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. The Avandia debate: an unhappy conclusion. Bloomgarden Z; Handelsman Y J Diabetes; 2010 Dec; 2(4):221-2. PubMed ID: 20923505 [No Abstract] [Full Text] [Related]
11. Thiazolidinediones and cardiovascular risk: will the evidence so far available modify treatment strategies for type 2 diabetes? Vaccaro O; Riccardi G Nutr Metab Cardiovasc Dis; 2008 Feb; 18(2):85-7. PubMed ID: 18280715 [No Abstract] [Full Text] [Related]
12. Rosiglitazone and cardiotoxicity--weighing the evidence. Nathan DM N Engl J Med; 2007 Jul; 357(1):64-6. PubMed ID: 17551161 [No Abstract] [Full Text] [Related]
13. Rosiglitazone. Simon D Prim Care Diabetes; 2009 May; 3(2):123-4. PubMed ID: 19482530 [No Abstract] [Full Text] [Related]
14. [Rosiglitazone--statistics for benefits and problems]. Hjelmesaeth J; Røislien J Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2702-3. PubMed ID: 17952157 [No Abstract] [Full Text] [Related]
15. The Yin and the Yang of CV risks in patients with diabetes. Dangi-Garimella S Am J Manag Care; 2014 May; 20(8 Spec No.):E6. PubMed ID: 25617925 [No Abstract] [Full Text] [Related]
16. [The PPARgamma receptor agonists and prevention of cardio-vascular complications in patients with type 2 diabetes. The results of the PROactive study]. Szymborska-Kajanek A; Strojek K Kardiol Pol; 2006 Mar; 64(3):322-5; discussion 325-6. PubMed ID: 16583340 [No Abstract] [Full Text] [Related]
17. [The effects of thiazolidinedione from the cardiologic viewpoint]. Ziegler R Med Monatsschr Pharm; 2005 Oct; 28(10):365. PubMed ID: 16245456 [No Abstract] [Full Text] [Related]
18. Type 2 diabetes, thiazolidinediones: bad to the bone? Watts NB; D'Alessio DA J Clin Endocrinol Metab; 2006 Sep; 91(9):3276-8. PubMed ID: 16960122 [No Abstract] [Full Text] [Related]